Alvotech (ALVO) News Today $13.36 +0.09 (+0.68%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Alvotech (NASDAQ:ALVO) Sees Significant Growth in Short InterestAlvotech (NASDAQ:ALVO - Get Free Report) was the recipient of a significant growth in short interest in December. As of December 31st, there was short interest totalling 436,500 shares, a growth of 244.2% from the December 15th total of 126,800 shares. Approximately 0.4% of the company's stock are short sold. Based on an average trading volume of 117,000 shares, the days-to-cover ratio is currently 3.7 days.January 13, 2025 | marketbeat.comAlvotech (NASDAQ:ALVO) Shares Gap Up - What's Next?Alvotech (NASDAQ:ALVO) Shares Gap Up - Still a Buy?January 8, 2025 | marketbeat.comAlvotech Eyes Growth As Product Revenue Soars And New Launches Approach - Will The Stock Follow? January 2, 2025 | rttnews.comAlvotech (NASDAQ:ALVO) Short Interest UpdateAlvotech (NASDAQ:ALVO - Get Free Report) saw a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 126,800 shares, a growth of 48.8% from the November 30th total of 85,200 shares. Based on an average daily volume of 113,800 shares, the short-interest ratio is presently 1.1 days. Currently, 0.1% of the company's stock are short sold.December 28, 2024 | marketbeat.comAlvotech (NASDAQ:ALVO) Shares Gap Up - Still a Buy?Alvotech (NASDAQ:ALVO) Shares Gap Up - Time to Buy?December 23, 2024 | marketbeat.comAlvotech Joins Nasdaq Biotechnology Index, Boosting Industry PresenceDecember 23, 2024 | tipranks.comAlvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024December 23, 2024 | gurufocus.comAlvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024December 23, 2024 | investing.comAlvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024December 23, 2024 | globenewswire.comAlvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024December 23, 2024 | globenewswire.comShort Interest in Alvotech (NASDAQ:ALVO) Rises By 47.8%Alvotech (NASDAQ:ALVO - Get Free Report) saw a significant increase in short interest in the month of November. As of November 15th, there was short interest totalling 116,800 shares, an increase of 47.8% from the October 31st total of 79,000 shares. Currently, 0.1% of the company's shares are short sold. Based on an average daily volume of 94,800 shares, the short-interest ratio is presently 1.2 days.November 29, 2024 | marketbeat.comNorthland Securities Keeps Their Buy Rating on Alvotech (ALVO)November 25, 2024 | markets.businessinsider.comAlvotech's Position In The Coming Biosimilar Gold RushNovember 21, 2024 | seekingalpha.comAlvotech Third Quarter 2024 Earnings: US$0.041 loss per share (vs US$0.81 loss in 3Q 2023)November 16, 2024 | finance.yahoo.comAlvotech (ALVO) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic AdvancementsNovember 16, 2024 | finance.yahoo.comNorthland Securities Reaffirms Their Buy Rating on Alvotech (ALVO)November 16, 2024 | markets.businessinsider.comAlvotech Reports Strong Revenue Growth in 2024November 16, 2024 | markets.businessinsider.comQ3 2024 Alvotech SA Earnings CallNovember 15, 2024 | finance.yahoo.comAlvotech (ALVO) Q3 2024 Earnings Call TranscriptNovember 14, 2024 | seekingalpha.comAlvotech Showcases Strong Financial Growth and ExpansionNovember 14, 2024 | markets.businessinsider.comBarclays Sticks to Their Buy Rating for Alvotech (ALVO)November 13, 2024 | markets.businessinsider.comAlvotech Reports Financial Results for the First Nine Months of 2024November 13, 2024 | markets.businessinsider.comAlvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore's HealthCONx Conference on December 5, 2024November 7, 2024 | globenewswire.comAlvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore's HealthCONx Conference on December 5, 2024November 7, 2024 | globenewswire.comEMA accepts Alvotech and Advanz Pharma’s AVT05 MAANovember 6, 2024 | msn.comAlvotech announces EMA acceptance of MAA for AVT05November 5, 2024 | markets.businessinsider.comAlvotech’s AVT05 Biosimilar Application Accepted by EMANovember 4, 2024 | markets.businessinsider.comEuropean Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)November 4, 2024 | globenewswire.comEuropean Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)November 4, 2024 | globenewswire.comAlvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024October 25, 2024 | globenewswire.comAlvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024October 25, 2024 | globenewswire.comAlvotech and Teva Secure FDA Approval for SELARSDIOctober 23, 2024 | markets.businessinsider.comAlvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)October 22, 2024 | globenewswire.comAlvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)October 22, 2024 | globenewswire.comAlvotech (ALVO) Gets a Buy from BarclaysOctober 17, 2024 | markets.businessinsider.comSouth Korean company Dong-A ST wins FDA approval for Stelara biosimilarOctober 12, 2024 | msn.comEuropean Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®October 10, 2024 | globenewswire.comEuropean Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®October 10, 2024 | globenewswire.comAlvotech (NASDAQ:ALVO) Shares Sold by Marshall Wace LLPMarshall Wace LLP reduced its position in Alvotech (NASDAQ:ALVO - Free Report) by 84.4% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 38,992 shares of the company's stock after selling 211,131 shares during the period. Marshall Wace LLP owned about 0.12% of AlOctober 10, 2024 | marketbeat.comAlvotech (NASDAQ:ALVO) Stock Quotes, Forecast and News SummaryOctober 5, 2024 | benzinga.comAlvotech (ALVO) Shares Up 3.77% on Oct 2October 2, 2024 | gurufocus.comFresenius Kabi wins FDA approval for Stelara biosimilar OtulfiOctober 2, 2024 | msn.comAlvotech (NASDAQ:ALVO) Shares Sold by Sculptor Capital LPSculptor Capital LP lowered its stake in Alvotech (NASDAQ:ALVO - Free Report) by 51.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 945,098 shares of the company's stock after selling 1,001,064 shares during the quartSeptember 27, 2024 | marketbeat.comAlvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio®September 25, 2024 | globenewswire.comAlvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio®September 25, 2024 | globenewswire.comAlvotech (NASDAQ:ALVO) Short Interest Up 108.1% in AugustAlvotech (NASDAQ:ALVO - Get Free Report) saw a large growth in short interest during the month of August. As of August 15th, there was short interest totalling 135,900 shares, a growth of 108.1% from the July 31st total of 65,300 shares. Based on an average trading volume of 131,500 shares, the short-interest ratio is presently 1.0 days. Approximately 0.1% of the shares of the stock are sold short.August 28, 2024 | marketbeat.comAlvotech: Steady Progress Offers A Good Chance Of UpsideAugust 26, 2024 | seekingalpha.comAlvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceAugust 26, 2024 | globenewswire.comAlvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceAugust 26, 2024 | globenewswire.comAlvotech (ALVO.IC)August 22, 2024 | uk.finance.yahoo.com Get Alvotech News Delivered to You Automatically Sign up to receive the latest news and ratings for ALVO and its competitors with MarketBeat's FREE daily newsletter. Email Address ALVO Media Mentions By Week ALVO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALVO News Sentiment▼1.000.57▲Average Medical News Sentiment ALVO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALVO Articles This Week▼03▲ALVO Articles Average Week Get Alvotech News Delivered to You Automatically Sign up to receive the latest news and ratings for ALVO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies GMAB News Today VTRS News Today MRNA News Today ITCI News Today SMMT News Today RDY News Today CTLT News Today SRPT News Today QGEN News Today PCVX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALVO) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredThis coin could surge during Trump’s first week in office.Juan has never had a losing trade on Bitcoin. And he booked gains of 312% on Chainlink … Now, he says one v...Weiss Ratings | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alvotech Please log in to your account or sign up in order to add this asset to your watchlist. Share Alvotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
